{
  "question_stem": {
    "en": "A 65-year-old woman comes to the emergency department due to left leg pain and swelling for the past day. She has had no trauma or fever. The patient has a history of hypertension, congestive heart failure, type 2 diabetes mellitus, and osteoporosis. Family history is notable for breast cancer in her mother and sister. She takes multiple medications. Temperature is 37.8 C (100 F), blood pressure is 130/80 mm Hg, and pulse is 99/min. Pulse oximetry shows 98% on ambient air. The lungs are clear to auscultation, and heart sounds are normal without murmur. There is tenderness and edema of the left lower extremity up to the mid thigh. Venous Doppler ultrasonography reveals an occluding thrombus in the left femoral and popliteal veins. Which of the following pharmacotherapies most likely contributed to this patient's current condition?",
    "zh": "一位65岁女性因左腿疼痛和肿胀一天前来急诊。她没有外伤或发烧。患者有高血压、充血性心力衰竭、2型糖尿病和骨质疏松症病史。家族史值得注意的是她母亲和姐妹患有乳腺癌。她服用多种药物。体温37.8°C（100°F），血压130/80 mmHg，脉搏99次/分。脉搏血氧饱和度在环境空气中为98%。肺部听诊清澈，心音正常，无杂音。左下肢出现压痛和水肿，直至大腿中部。静脉多普勒超声检查显示左股静脉和腘静脉有阻塞性血栓。以下哪种药物疗法最有可能导致患者目前的状况？"
  },
  "question": {
    "en": "Which of the following pharmacotherapies most likely contributed to this patient's current condition?",
    "zh": "以下哪种药物疗法最有可能导致患者目前的状况？"
  },
  "options": {
    "A": {
      "en": "Alendronate",
      "zh": "阿仑膦酸钠"
    },
    "B": {
      "en": "Chlorthalidone",
      "zh": "氯噻酮"
    },
    "C": {
      "en": "Empagliflozin",
      "zh": "恩格列净"
    },
    "D": {
      "en": "Liraglutide",
      "zh": "利拉鲁肽"
    },
    "E": {
      "en": "Raloxifene",
      "zh": "雷洛昔芬"
    },
    "F": {
      "en": "Sacubitril-valsartan",
      "zh": "沙库巴曲缬沙坦"
    },
    "G": {
      "en": "Spironolactone",
      "zh": "螺内酯"
    }
  },
  "correct_answer": "E",
  "explanation": {
    "en": "Selective estrogen receptor modulators (SERMs), such as raloxifene and tamoxifen, are nonsteroidal compounds that bind to estrogen receptors and exhibit estrogen antagonist and agonist properties in a tissue-specific manner. Raloxifene has estrogen agonist activity on bone, inhibiting bone resorption and improving bone mineral density while exhibiting estrogen antagonist activity in the breast and endometrial tissue.\n\nMedicines with estrogen agonist activity, including SERMs, oral contraceptives, and hormone replacement therapy, cause a prothrombotic state and can increase the risk for VENOUS THROMBOEMBOLISM (VTE). Proposed mechanisms include increased levels of clotting factors (eg, prothrombin; fibrinogen; factor VII, VIII, X) and activated protein C resistance. Current or prior thromboembolic disorders are contraindications to SERM use.\n\n(Choice A) Bisphosphonates (eg, alendronate) inhibit osteoclast-mediated bone resorption. Side effects include hypocalcemia, esophagitis, and osteonecrosis of the jaw. Bisphosphonates have no estrogenic activity and do not increase the risk for VTE.\n\n(Choice B) Thiazide diuretics (eg, chlorthalidone) inhibit Na+/Cl- cotransporters in the distal convoluted tubule, decreasing reabsorption of Na+ and increasing reabsorption of calcium, which can be beneficial in patients with osteoporosis. Side effects include electrolyte abnormalities, hyperglycemia, and hyperlipidemia.\n\n(Choice C) Sodium-glucose cotransporter 2 inhibitors (eg, empagliflozin) reduce reabsorption of glucose in the proximal renal tubule, leading to urinary glucose excretion. Side effects include urinary tract and genital mycotic infections as well as hypotension.\n\n(Choice D) Glucagon-like peptide-1 (GLP-1) is released by the small intestine in response to food and induces glucose-dependent insulin release from pancreatic beta cells. GLP-1 agonists (eg, liraglutide) lower blood glucose with little hypoglycemia risk, but can cause gastrointestinal upset and weight loss.\n\n(Choice F) Sacubitril is a neprilysin inhibitor that increases atrial natriuretic peptide and brain natriuretic peptide levels (thereby promoting diuresis and vasodilation) in patients in heart failure. It is administered with an angiotensin II receptor blocker (valsartan) to offset the associated increase in angiotensin II levels. Side effects include cough, hyperkalemia, and renal impairment.\n\n(Choice G) Spironolactone is an aldosterone antagonist used in patients with heart failure. It has prominent anti-androgenic effects, which can lead to gynecomastia in male patients due to unopposed estrogenic effects on breast tissue. However, it has minimal effects on estrogen levels and does not increase the risk of VTE.\n\nEducational objective:\n\nRaloxifene is a selective estrogen receptor modulator (SERM) that has estrogen agonist activity on bone and decreases bone resorption. Medicines with estrogen agonist activity, including SERMs, oral contraceptives, and hormone replacement therapy, can increase the risk for venous thromboembolism.",
    "zh": "选择性雌激素受体调节剂（SERMs），如雷洛昔芬和他莫昔芬，是非甾体化合物，可与雌激素受体结合，并在组织特异性方式下表现出雌激素拮抗剂和激动剂特性。雷洛昔芬对骨骼具有雌激素激动剂活性，抑制骨吸收并改善骨矿物质密度，同时在乳房和子宫内膜组织中表现出雌激素拮抗剂活性。\n\n具有雌激素激动剂活性的药物，包括 SERMs、口服避孕药和激素替代疗法，会导致促血栓形成状态，并可能增加静脉血栓栓塞（VTE）的风险。拟议的机制包括凝血因子水平升高（例如，凝血酶原；纤维蛋白原；因子 VII、VIII、X）和活化蛋白 C 抵抗。目前或既往血栓栓塞性疾病是 SERM 使用的禁忌症。\n\n（选项 A）双膦酸盐（例如，阿仑膦酸钠）抑制破骨细胞介导的骨吸收。副作用包括低钙血症、食管炎和颌骨骨坏死。双膦酸盐没有雌激素活性，不会增加 VTE 的风险。\n\n（选项 B）噻嗪类利尿剂（例如，氯噻酮）抑制远曲小管中的 Na+/Cl- 共转运蛋白，减少 Na+ 的再吸收，并增加钙的再吸收，这可能对骨质疏松症患者有益。副作用包括电解质异常、高血糖和高脂血症。\n\n（选项 C）钠-葡萄糖协同转运蛋白 2 抑制剂（例如，恩格列净）减少近端肾小管中葡萄糖的再吸收，导致尿糖排泄。副作用包括泌尿系统和生殖器真菌感染以及低血压。\n\n（选项 D）胰高血糖素样肽-1 (GLP-1) 由小肠释放以响应食物，并诱导胰腺β细胞释放葡萄糖依赖性胰岛素。GLP-1 激动剂（例如，利拉鲁肽）可降低血糖，低血糖风险很小，但可引起胃肠道不适和体重减轻。\n\n（选项 F）沙库巴曲是一种脑啡肽酶抑制剂，可增加心力衰竭患者的房利钠肽和脑利钠肽水平（从而促进利尿和血管舒张）。它与血管紧张素 II 受体阻滞剂（缬沙坦）一起给药，以抵消相关的血管紧张素 II 水平升高。副作用包括咳嗽、高钾血症和肾功能损害。\n\n（选项 G）螺内酯是一种用于心力衰竭患者的醛固酮拮抗剂。它具有显着的抗雄激素作用，由于对乳腺组织的未对抗的雌激素作用，可导致男性患者出现男性乳房发育症。然而，它对雌激素水平的影响很小，并且不会增加 VTE 的风险。\n\n教育目标：\n\n雷洛昔芬是一种选择性雌激素受体调节剂（SERM），对骨骼具有雌激素激动剂活性，可减少骨吸收。具有雌激素激动剂活性的药物，包括 SERMs、口服避孕药和激素替代疗法，可增加静脉血栓栓塞的风险。"
  },
  "summary": {
    "en": "This question tests the knowledge of medications that increase the risk of venous thromboembolism (VTE), specifically focusing on selective estrogen receptor modulators (SERMs) like raloxifene. It requires understanding the mechanism of action and adverse effects of various medications.\n\nTo solve this question, identify the patient's risk factors for VTE and consider the medications that can exacerbate this risk. Recognize that SERMs have estrogen agonist activity, which can promote a prothrombotic state and increase the likelihood of VTE.",
    "zh": "本题考察了增加静脉血栓栓塞 (VTE) 风险的药物的知识，特别侧重于雷洛昔芬等选择性雌激素受体调节剂 (SERMs)。它需要了解各种药物的作用机制和不良反应。\n\n为了解决这个问题，确定患者的 VTE 危险因素，并考虑可能加剧这种风险的药物。认识到 SERMs 具有雌激素激动剂活性，这可能促进促血栓形成状态并增加 VTE 的可能性。"
  },
  "tags": "Venous thromboembolism; Raloxifene; Selective estrogen receptor modulators; Osteoporosis; Prothrombotic state; Endocrinology; Hematology; Adverse drug effects",
  "category": "Endo",
  "question_id": "14920",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Endo 23\\14920",
  "extracted_at": "2025-11-05T14:00:12.330483",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T17:37:29.042200",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}